Trial Profile

First Phase II clinical trial of AL001 for patients with mild to moderate Alzheimer's disease

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lithium cocrystal Alzamend Neuro (Primary)
Indications Alzheimer's disease; Bipolar disorders; Major depressive disorder; Post-traumatic stress disorders
Focus Registrational; Therapeutic Use

19 May 2025 According to an Alzamend Neuro media release, Status changed from not yet recruiting to completed.
19 May 2025 According to an Alzamend Neuro media release, results from this study of AL001 in Alzheimer's patients and healthy subjects identified a maximum tolerated dose (MTD), as assessed by an independent safety review committee.
13 May 2025 According to an Alzamend Neuro media release, topline data from this trial expected by year end.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com